Why use it

CLL follows a highly heterogeneous clinical course — some patients never require treatment and have near-normal life expectancy, while others progress rapidly despite therapy. The CLL-IPI provides validated, internationally endorsed prognostic stratification that goes beyond clinical staging to incorporate critical biological markers (TP53, IGHV) that directly inform treatment decisions, clinical trial eligibility, and patient counseling. It is endorsed by the iwCLL (International Workshop on CLL) guidelines and the European Society for Medical Oncology (ESMO).

About

The International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) was developed by an international working group combining data from 8 clinical trials and registry cohorts comprising 3,472 patients. Published in The Lancet Oncology in 2016, the CLL-IPI integrates five independent prognostic factors — TP53 deletion/mutation status, IGHV mutational status, serum β2-microglobulin, clinical stage (Rai or Binet), and age — into a single weighted score ranging from 0 to 10 that stratifies patients into four risk groups: low, intermediate, high, and very high risk. The 5-year overall survival for these groups is approximately 93%, 79%, 63%, and 23%, respectively, demonstrating marked survival separation. The CLL-IPI was validated in independent cohorts and is applicable at diagnosis. It provides superior prognostic discrimination compared to clinical stage alone (Rai/Binet) and integrates the most clinically relevant modern biological markers.

When to use

At initial diagnosis of CLL to establish prognostic risk group
Before initiating therapy to inform treatment intensity decisions and clinical trial eligibility
Patient counseling about expected disease course and surveillance interval
Selecting patients for novel targeted therapy (BTK inhibitors, BCL-2 inhibitors) vs. watchful waiting
Clinical trial enrollment stratification
Reassessment after clonal evolution (acquisition of new cytogenetic/molecular abnormalities)

Formula

CLL-IPI Score: TP53 deletion or mutation: +4 points IGHV unmutated (≥98% germline identity): +2 points β2-microglobulin >3.5 mg/L: +2 points Rai stage ≥I or Binet stage B or C: +1 point Age >65 years: +1 point Total: 0–10 Risk Groups: 0–1: Low risk (~93% 5-year OS) 2–3: Intermediate (~79% 5-year OS) 4–6: High risk (~63% 5-year OS) 7–10: Very high risk (~23% 5-year OS)

Pearls & pitfalls

TP53 deletion (del17p) or TP53 mutation is the most critical adverse prognostic marker in CLL — it renders the disease resistant to conventional chemoimmunotherapy (FCR, BR). Always assess TP53 before treatment initiation.
IGHV unmutated status (sequence identity ≥98% to germline) carries a significantly worse prognosis than IGHV mutated status and predicts poor response to FCR-based chemotherapy.
β2-microglobulin >3.5 mg/L is a marker of tumor burden and immune dysfunction — it reflects disease activity and is an independent prognostic factor.
The CLL-IPI is a PROGNOSTIC tool for overall survival — it should not be used alone to decide WHEN to start treatment. The iwCLL treatment initiation criteria (Hallek 2018) must be applied separately.
TP53 mutation (without del17p) carries the same adverse prognostic significance as del17p — comprehensive TP53 assessment should include both FISH and sequencing.
Low-risk CLL-IPI does not mean the patient will never need treatment — it means they have a favorable prognosis at diagnosis. Progressive disease can still develop.
The CLL-IPI score should be calculated at diagnosis when all five variables are most reliably assessable. Serial reassessment may be appropriate if clinical status changes or new molecular data become available.
β2-microglobulin can be elevated by renal impairment independently of CLL activity — interpret in the context of renal function.
Rai stage 0 (lymphocytosis only) or Binet stage A alone without other adverse features confers very favorable prognosis (often score 0–1).

Next steps

Low Risk (Score 0–1): ~93% 5-year OS. Watchful waiting appropriate for most patients. No treatment indicated in early-stage asymptomatic CLL. Regular monitoring every 3–6 months (CBC, clinical exam). Intermediate Risk (Score 2–3): ~79% 5-year OS. Continued watchful waiting for asymptomatic patients. Active treatment when iwCLL criteria for treatment initiation are met. High Risk (Score 4–6): ~63% 5-year OS. Higher vigilance for treatment initiation criteria. Assess TP53/IGHV if not already done. Consider enrollment in clinical trials. Very High Risk (Score 7–10): ~23% 5-year OS. TP53 deletion/mutation likely present. BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) or BCL-2 inhibitors (venetoclax + obinutuzumab) are preferred first-line — NOT alkylating agent-based chemoimmunotherapy. Early specialist hematology referral.

Evidence

International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790. PMID:27185642. Derivation and validation: 3,472 patients across 8 cohorts. C-index 0.73. 5-year OS: Low 93%, Intermediate 79%, High 63%, Very High 23%. Validated in multiple independent cohorts across treatment eras.

References

International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI). Lancet Oncol. 2016;17(6):779-790. — link
Hallek M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. — link
Woyach JA et al. Ibrutinib versus ibrutinib plus rituximab in symptomatic, treatment-naive CLL. J Clin Oncol. 2018;36(31):3137-3147. — link

International Prognostic Index for CLL (CLL-IPI)

Calculator